Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | DHODH | Q02127 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | CASR | P41180 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16589271 | 0.84 | KMT2A (0.36) | HTR2CKMT2ADHODHL3MBTL1MEN1 | |
| SCHEMBL16592134 | 0.78 | HTR2C (0.48) | HTR2CKMT2AL3MBTL1MEN1GPR84 | |
| SCHEMBL15075409 | 0.70 | KDM4E (0.41) | HTR2CKMT2AMEN1GPR84GSK3B | |
| SCHEMBL8901945 | 0.68 | SMN1; SMN2 (0.42) | DHODHL3MBTL1EGFRMETKDM4E | |
| SCHEMBL16592161 | 0.68 | CASR (0.55) | HTR2CBACE1CASR | |
| SCHEMBL14444102 | 0.64 | CYP1A2 (0.59) | KMT2AGPR84KDM4EPOLB | |
| SCHEMBL16592145 | 0.63 | HTR2C (0.64) | HTR2CL3MBTL1KDM4E | |
| SCHEMBL16592155 | 0.62 | HTR2C (0.43) | HTR2C | |
| SCHEMBL8851892 | 0.61 | CYP1A2 (0.54) | KMT2AL3MBTL1MEN1GPR84 | |
| SCHEMBL1254359 | 0.61 | TAAR1 (0.57) | HTR2CGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150087639-A1 | Nitrogenous Heterocyclic Derivatives And Their Application In Drugs | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087639-A1 | Nitrogenous Heterocyclic Derivatives And Their Application In Drugs | TNNC1, TNNI3, IAPP | HTR2C 4209/4885KMT2A 2967/4885DHODH 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.